Сравнение
Eloralintide vs. Survodutide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
нет данных
2179963-22-7
Молекулярная масса
нет данных
4727 g/mol
Период полувыведения
нет данных
168 h
Последовательность
нет данных
modifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteМеханизм действия
Eloralintide
Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
2
4
из них на людях
1
4
Зафиксированные эффекты
2
3
Открытые противоречия
0
1
Задокументированные нежелательные явления
1
2
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Eloralintide and Survodutide?
- Eloralintide is classified as "Метаболизм", while Survodutide is classified as "Метаболизм". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Eloralintide or Survodutide?
- The highest available evidence level is "РКИ на людях" for Eloralintide and "РКИ на людях" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Eloralintide and Survodutide in Germany and the United States?
- Германия: Eloralintide — Не одобрено, Survodutide — Не одобрено. США: Eloralintide — Не одобрено, Survodutide — Не одобрено. These are factual summaries with source and review date on the individual pages.